

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

REC'D 14 FEB 2006

WIPO

PCT

Applicant's or agent's file reference 10104SG281/KJR(PDR)/ss	<b>FOR FURTHER ACTION</b>		See Form PCT/IPEA/416
International application No. PCT/SG2005/000051	International filing date (day/month/year) 21 February 2005	Priority date (day/month/year) 25 February 2004	
International Patent Classification (IPC) or national classification and IPC  Int. Cl.  <b>C07K 14/42</b> (2006.01) <b>C07K 14/435</b> (2006.01) <b>C07K 14/765</b> (2006.01)			
Applicant NATIONAL UNIVERSITY OF SINGAPORE et al.			

1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 3 sheets, including this cover sheet.
3. This report is also accompanied by ANNEXES, comprising:
  - a. ☒ (sent to the applicant and to the International Bureau) a total of 9 sheets, as follows:
    - ☒ sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).
    - ☐ sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.
  - b. ☐ (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or table related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).
4. This report contains indications relating to the following items:
 

<input checked="" type="checkbox"/> Box No. I	Basis of the report
<input type="checkbox"/> Box No. II	Priority
<input type="checkbox"/> Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
<input type="checkbox"/> Box No. IV	Lack of unity of invention
<input checked="" type="checkbox"/> Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
<input type="checkbox"/> Box No. VI	Certain documents cited
<input type="checkbox"/> Box No. VII	Certain defects in the international application
<input type="checkbox"/> Box No. VIII	Certain observations on the international application

Date of submission of the demand 12 August 2005	Date of completion of this report 23 January 2006
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer  <b>MARIE-ANNE FAM</b> Telephone No. (02) 6283 2254

**Box No. I**      **Basis of the report**1. With regard to the **language**, this report is based on:☒ The international application in the language in which it was filed☐ A translation of the international application into \_\_\_\_\_, which is the language of a translation furnished for the purposes of:☐ international search (under Rules 12.3(a) and 23.1 (b))☐ publication of the international application (under Rule 12.4(a))☐ international preliminary examination (Rules 55.2(a) and/or 55.3(a))2. With regard to the **elements** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:☐ the international application as originally filed/furnished☒ the description:pages **1-5, 7-19** as originally filed/furnishedpages\* **6** received by this Authority on **15 August 2005** with the letter of **12 August 2005**

pages\* received by this Authority on \_\_\_\_\_ with the letter of \_\_\_\_\_

☒ the claims:

pages as originally filed/furnished

pages\* as amended (together with any statement) under Article 19

pages\* **20-27** received by this Authority on **15 August 2005** with the letter of **12 August 2005**

pages\* received by this Authority on \_\_\_\_\_ with the letter of \_\_\_\_\_

☒ the drawings:pages **1/10-10/10** as originally filed/furnished

pages\* received by this Authority on \_\_\_\_\_ with the letter of \_\_\_\_\_

pages\* received by this Authority on \_\_\_\_\_ with the letter of \_\_\_\_\_

☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.3. ☐ The amendments have resulted in the cancellation of:☐ the description, pages☐ the claims, Nos.☐ the drawings, sheets/figs☐ the sequence listing (*specify*):☐ any table(s) related to the sequence listing (*specify*):4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).☐ the description, pages☐ the claims, Nos.☐ the drawings, sheets/figs☐ the sequence listing (*specify*):☐ any table(s) related to the sequence listing (*specify*):

\* If item 4 applies, some or all of those sheets may be marked "superseded."

**Box No. V** Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

## 1. Statement

Novelty (N)	Claims 1-55	YES
	Claims -	NO
Inventive step (IS)	Claims 1-55	YES
	Claims -	NO
Industrial applicability (IA)	Claims 1-55	YES
	Claims -	NO

## 2. Citations and explanations (Rule 70.7)

**Novelty and Inventive Step**

The following documents were identified in the search report:

- D1 Biophysical Chemistry  
D2 Biotechnology and Bioengineering

The present invention relates to methods for predicting crystallisation conditions for proteins and other biomacromolecules. Current methods for determining these conditions usually employ the second virial coefficient  $B_{22}$ . However this coefficient is based only on intermolecular interactions and hence does not always provide reliable results.

In contrast, the present invention uses methods that are based on both intermolecular interactions and kinetic effects. In particular, the methods monitor changes in surface tension and/or surface pressure. This enables crystallisation conditions to be predicted with greater reliability. Neither D1 nor D2 discloses methods as defined by the present claims. Consequently claims 1-55 are considered novel and inventive in view of the prior art.

**Industrial Applicability**

Claims 1-55 meet the requirements for industrial applicability.

The primary features of a first embodiment of the invention of a method of predicting biomacromolecule crystallization conditions and for crystallizing biomacromolecules are provided hereinafter with reference to FIG. 1A in FIGs. 2–6. The primary features of a second embodiment of the invention are provided hereinafter with reference to FIG. 1B in FIGs. 2–5 and FIGs. 7–15. In the first embodiment, a crystal equilibrium condition in FIG. 1A is expressed by means of a macromolecule solubility curve serving as a boundary separating two regions of experimental parameter values: a region where crystallization can occur, and a region where crystallization cannot occur.

The method described in the first embodiment establishes a biomacromolecule equilibrium concentration in the context of the applied experimental conditions. The biomacromolecule concentration to be used for crystallization must exceed the obtained equilibrium value. In a second embodiment, an aggregation boundary condition in FIG. 1B is expressed by means of a window of experimental parameter values above which the amorphous aggregation is likely to occur. The terms “aggregation” and “amorphous aggregation” are used interchangeably.

#### Theoretical Introduction

In attempts to crystallize biomacromolecules from a solution, it is desirable to obtain as much as possible single crystals with as few defects as possible, and to avoid amorphous aggregations of molecules, since amorphous aggregates are not crystals. The present invention takes advantage of the property of biomacromolecules to have mixed hydrophobic and hydrophilic regions. This property results in a tendency for these molecules to assembly either in the bulk or at the surface of the solution. In this disclosure, the surface of the solution can be adjacent to another material or to empty space, and hence the surface can be in contact with a solid or with a liquid or with a gas, that is usually air. The surface of the solution has a surface tension and a surface pressure, which terms in this case include an interfacial tension or an interfacial pressure.

It is possible to define one or more assembly parameters that reach a critical response as increasingly more molecules participate in assembly formation. For example, the tendency of biomacromolecules to assembly in a solution can be monitored by taking surface tension or surface pressure measurements of the solution.

1. A method for predicting a crystal equilibrium condition for biomacromolecule crystallization and for crystallizing a biomacromolecule, comprising setting up at least one biomacromolecule solubility experiment comprising the steps of

5 a) preparing a solution of the biomacromolecule in a solvent, the solution having a biomacromolecule concentration,

b) selecting a variable quantity,

c) selecting an assembly parameter being one or more of a surface tension and a surface pressure,

10 d) monitoring a response of the assembly parameter while varying the variable quantity in a suitable way so that the response exhibits a transition,

e) obtaining an equilibrium biomacromolecule concentration based on the transition,

f) defining a crystal equilibrium condition according to which a biomacromolecule crystallization concentration exceeds the equilibrium biomacromolecule concentration, and crystallizing the biomacromolecule.

15 2. The method as claimed in Claim 1, wherein the solution has further a pH and a temperature, and the variable quantity is one of the biomacromolecule concentration, the pH and the temperature.

20 3. The method as claimed in Claim 2, wherein the solution further comprises an additive, the solution has an additive concentration, and the variable quantity is one of the biomacromolecule concentration, the pH, the temperature and the additive concentration.

4. The method as claimed in Claim 1, wherein the solution has a surface.

5. The method as claimed in Claim 4, wherein the biomacromolecule is not prone to unfolding at the surface of the solution.

25 6. The method as claimed in Claim 2 or Claim 3, wherein the transition is associated with a critical magnitude of the variable quantity.

7. The method as claimed in Claim 2 or Claim 3, wherein the transition is between a changing response of the assembly parameter and a substantially unchanging response of the assembly parameter.



8. The method as claimed in Claim 2 or Claim 3, wherein the transition is associated with a critical magnitude of the variable quantity, and further wherein the transition is between a changing response of the assembly parameter and a substantially unchanging response of the assembly parameter.
- 5 9. The method as claimed in Claim 8, wherein the substantially unchanging response corresponds to a substantially minimal value of the assembly parameter.
10. The method as claimed in Claim 8, further defining the crystal equilibrium condition in terms of the critical magnitude, wherein the crystal equilibrium condition prescribes that no crystallization occurs when the variable quantity is smaller than the critical magnitude.
- 10 11. The method as claimed in Claim 10 wherein the variable quantity is the biomacromolecule concentration, and consequently the equilibrium biomacromolecule concentration equals the critical magnitude.
12. The method as claimed in Claim 10 wherein the variable quantity is not the biomacromolecule concentration, and consequently the equilibrium biomacromolecule
- 15 concentration equals the biomacromolecule concentration.
13. The method as claimed in Claim 1, wherein the biomacromolecule to be crystallized is a protein.
14. The method as claimed in Claim 13, wherein the protein has a weight less than 200 kDalton.
- 20 15. The method as claimed in Claim 14, wherein the protein is one of a lysozyme and a concanavalin A.
16. The method as claimed in Claim 1, wherein the biomacromolecule to be crystallized is a polypeptide.
17. The method as claimed in Claim 1, wherein the biomacromolecule to be crystallized is a
- 25 nucleic acid.
18. The method as claimed in Claim 1, wherein the biomacromolecule to be crystallized is a virus.
19. The method as claimed in Claim 1, wherein the biomacromolecule to be crystallized is a virus fragment.
- 30 20. The method as claimed in Claim 3, wherein the additive is a salt.
21. The method as claimed in Claim 3, wherein the additive comprises organic molecules.
22. The method as claimed in Claim 3, wherein the additive comprises polymers.

23. A method for predicting a crystal equilibrium condition for protein crystallization and for crystallizing a protein, comprising setting up at least one biomacromolecule solubility experiment, comprising the steps of

5 a) preparing a solution of the protein in a solvent, the solution further comprising an additive, the solution having a protein concentration, an additive concentration, a pH and a temperature, the solution having a surface, the surface having a surface tension and a surface pressure, the protein being not prone to unfolding at the surface,

b) defining an assembly parameter to be one of the surface tension and the surface pressure,

10 c) selecting a first variable quantity and a second variable quantity from the protein concentration, the additive concentration, the pH and the temperature,

d) varying the first variable quantity in a suitable way so that the assembly parameter exhibits a transition between a changing response and a substantially unchanging response, wherein the substantially unchanging response corresponds to a first substantially minimal value of the assembly parameter, the transition being associated with a first critical magnitude of the first variable quantity,

15 e) varying the second variable quantity in a suitable way so that the assembly parameter exhibits a transition between a changing response and a substantially unchanging response, wherein the substantially unchanging response corresponds to a second substantially minimal value of the assembly parameter, the transition being associated with a second critical magnitude of the second variable quantity,

20 f) constructing a solubility curve comprising points, each point being a pair of the first critical magnitude and the second critical magnitude, in order to assist in defining a crystal equilibrium condition,

25 g) obtaining an equilibrium protein concentration and defining the crystal equilibrium condition which is based on the solubility curve, and which prescribes that crystallization occurs when the first variable quantity exceeds the first critical magnitude of the pair, and the second variable quantity exceeds the second critical magnitude of the pair, and crystallizing the protein using a protein crystallization concentration exceeding the equilibrium protein concentration.

30 24. The method as claimed in Claim 23, where in step (c) the protein concentration is one of the first variable quantity and the second variable quantity, and hence in step (g) the

equilibrium protein concentration is correspondingly one of the first critical magnitude and the second critical magnitude.

5 25. The method as claimed in Claim 23, where in step (c) the protein concentration is not one of the first variable quantity and the second variable quantity, and hence in step (g) the equilibrium protein concentration is the protein concentration.

26. The method as claimed in Claim 23, wherein the protein is one of the lysozyme and the concanavalin A and the additive is a salt.

10 27. A method for predicting an aggregation boundary condition for biomacromolecule crystallization and for crystallizing a biomacromolecule, comprising setting up at least one aggregation boundary condition experiment comprising

a) preparing a solution of the biomacromolecule,

b) selecting a variable quantity,

15 c) selecting an assembly parameter being one or more of a surface tension and a surface pressure,

d) measuring the assembly parameter at different times,

e) registering an equilibrium assembly parameter

20 f) deriving a crystallization coefficient from the equilibrium assembly parameter, the crystallization coefficient being associated with the variable quantity,

g) using an aggregation indicator to define an aggregation boundary condition for the biomacromolecule, the aggregation boundary condition prescribing that an aggregation occurs when the crystallization coefficient associated with the variable quantity is larger than the aggregation indicator,

25 and crystallizing the biomacromolecule.

28. A method for predicting an aggregation boundary condition for biomacromolecule crystallization and for crystallizing a biomacromolecule, comprising setting up at least one aggregation boundary condition experiment comprising

30 a) preparing a solution of the biomacromolecule in a solvent, the solution having a biomacromolecule concentration and a surface, the surface having a surface pressure,

b) selecting a variable quantity,

c) obtaining the surface pressure at different times, while varying the variable quantity,

d) recording a time dependent equilibrium surface pressure which is associated with the variable quantity,



e) formulating a time-dependence profile based on the equilibrium surface pressure,  
5 which is associated with the variable quantity,

f) deriving from the time-dependence profile a crystallization coefficient of the  
biomacromolecule, that is associated with the variable quantity,

g) obtaining from the crystallization coefficient an aggregation indicator in order to  
define an aggregation boundary condition for the biomacromolecule, the aggregation  
10 boundary condition prescribing that an aggregation occurs when the crystallization  
coefficient associated with the variable quantity is larger than the aggregation indicator,  
and crystallizing the biomacromolecule.

29. The method as claimed in Claim 28, wherein the biomacromolecule is not prone to  
unfolding at the surface of the solution.

15 30. The method as claimed in Claim 28, wherein the solution further has pH and a  
temperature.

31. The method as claimed in Claim 28, wherein the biomacromolecule concentration is in  
the range 0.01 – 1.2 mg/ml.

20 32. The method as claimed in Claim 28, wherein the solution further comprises an additive  
and the solution has an additive concentration.

33. The method as claimed in Claim 30, wherein the variable quantity is one of the  
biomacromolecule concentration, the pH and the temperature.

34. The method as claimed in Claim 32, wherein the variable quantity is one of the  
biomacromolecule concentration, the additive concentration, the pH and the temperature.

25 35. The method as claimed in Claim 28, wherein the step of deriving the crystallization  
coefficient comprises the steps of

obtaining a diffusion time of the biomacromolecule,

obtaining an integration time of the biomacromolecule,

30 dividing the integration time by the diffusion time to obtain the crystallization coefficient of  
the biomacromolecule, that is associated with the variable quantity.

36. The method as claimed in Claim 28 wherein the time-dependence profile is given by  
 $\ln(1-p/p_{eq})$ , where  $\ln$  is the natural logarithm,  $p$  is the surface pressure and  $p_{eq}$  is an  
equilibrium surface pressure.

37. The method as claimed in Claim 36, where the step of deriving the crystallization coefficient comprises the steps of

constructing a plot of the time-dependence profile against a time,

identifying on the plot of the time-dependence profile a first substantially straight linear segment, a second substantially straight linear segment and a third substantially straight linear segment, where the second substantially straight linear segment is later in the time than the first substantially straight linear segment and the second substantially straight linear segment is later in the time than the third substantially straight linear segment,

equating a diffusion time to an inverse slope of the first substantially straight linear segment,

equating a penetration time to an inverse slope of the second substantially straight linear segment,

equating a rearrangement time to an inverse slope of the third substantially straight linear segment,

adding the penetration time and the rearrangement time to obtain an integration time

dividing the integration time by the diffusion time to obtain the crystallization coefficient of the biomacromolecule, that is associated with the variable quantity.

38. The method as claimed in Claim 28, wherein the biomacromolecule to be crystallized is a protein.

39. The method as claimed in Claim 38, wherein the protein has a weight less than 200 kDalton.

40. The method as claimed in Claim 39, wherein the protein is one of a lysozyme and a concanavalin A.

41. The method as claimed in Claim 28, wherein the biomacromolecule to be crystallized is a polypeptide.

42. The method as claimed in Claim 28, wherein the biomacromolecule to be crystallized is a nucleic acid.

43. The method as claimed in Claim 28, wherein the biomacromolecule to be crystallized is a virus.

44. The method as claimed in Claim 28, wherein the biomacromolecule to be crystallized is a virus fragment.

45. The method as claimed in Claim 32, wherein the additive is a salt.

46. The method as claimed in Claim 32, wherein the additive comprises organic molecules.

47. The method as claimed in Claim 32, wherein the additive comprises polymers.

48. The method as claimed in Claim 28, wherein the aggregation indicator is below 9.

49. The method as claimed in Claim 28, wherein the aggregation indicator is below 8.5.

5 50. The method as claimed in Claim 28, wherein the aggregation indicator is in a range from 4 to 9.

51. The method as claimed in Claim 28, wherein the aggregation indicator is in a range from 4.5 to 8.5.

10 52. A method for predicting an aggregation boundary condition for protein crystallization and for crystallizing a protein, comprising setting up at least one aggregation boundary condition experiment comprising

15 a) preparing a solution of the protein in a solvent, a salt, and a suitable buffer, the solution having a salt concentration, a protein concentration in a range 0.01—1.2 mg/ml, a pH and a temperature, the solution having a surface, the surface having a surface pressure, the protein not being prone to unfolding at the surface of the solution,

b) obtaining the surface pressure at different times, while varying the salt concentration,

c) recording a time-dependent equilibrium surface pressure, which corresponds with an equilibrium time, and which is associated with the salt concentration,

20 d) formulating a time-dependence profile, which is given by  $\ln(1-p/p_{eq})$ , where  $\ln$  is the natural logarithm,  $p$  is the surface pressure and  $p_{eq}$  is an equilibrium surface pressure, and which is associated with the salt concentration,

e) constructing a plot of the time-dependence profile against a time,

25 f) identifying on the plot a first substantially straight linear segment, a second substantially straight linear segment and a third substantially straight linear segment, where the second substantially straight linear segment is later in the time than the first substantially straight linear segment, and the third substantially straight linear segment is later in time than the second substantially straight linear segment,

g) equating a diffusion time to an inverse slope of the first substantially straight linear segment,

30 h) equating a penetration time to an inverse slope of the second substantially straight linear segment,

i) equating a rearrangement time to an inverse slope of the third substantially straight linear segment,

j) adding the penetration time and the rearrangement time to obtain an integration time

k) dividing the integration time by the diffusion time to obtain the crystallization coefficient of the protein, that is associated with the salt concentration,

5 g) obtaining from the crystallization coefficient an aggregation indicator in order to define an aggregation boundary condition for the protein, the aggregation boundary condition prescribing that an aggregation occurs when the crystallization coefficient associated with the salt concentration is larger than the aggregation indicator, the aggregation indicator being in a range from 4.5 to 8.5.

53. The method as claimed in Claim 52, wherein the protein is one of a lysozyme and a concanavalin A.

10 54. The biomacromolecule crystallized according to any one of the Claims 1—22 and 28—51.

55. The protein crystallized according to any one of the Claims 23—26, 52 and 53.